Clinical trial • Phase III • Oncology
Clinical trial in Cervical cancer
Phase III trial for Cervical cancer. 12 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Cervical cancer
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 14-05-2025
- First CTIS Authorization Date
- 19-08-2025
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 12
Recruitment
- Planned Sample Size
- 12
- Recruitment Window Months
- 18
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 12
Netherlands
- Earliest CTIS Part Ii Submission Date
- 28-07-2025
- Latest Decision Or Authorization Date
- 19-08-2025
- Processing Time Days
- 22
- Number Of Sites
- 1
- Number Of Participants
- 12
Sites
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Obstetrics & Gynecology
- Principal Investigator Name
- H.W. Nijman
- Principal Investigator Email
- h.w.nijman@umcg.nl
- Contact Person Name
- Prof. dr. H.W. Nijman
- Contact Person Email
- h.w.nijman@umcg.nl
- Number Of Participants
- 12
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Groningen
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- ESTRIOL for Cervical cancer
- Clinical trial in Cervical cancer
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer